John J McCabe
CIK 1205535 · Vice President, Finance · last filed 2019-12-06
John J McCabe is a Vice President, Finance who has filed 12 SEC Form 4 insider transactions across 2 companies since 2015. The most recent filing, for TORC, was dated Dec 6, 2019. Across all open-market trades the lifetime net is −$9.0K, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
EBIO price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
215 FIRST STREET, SUITE 400
CAMBRIDGE, MA 02142
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Adicet Bio, Inc. (TORC) Delisted | Vice President, Finance | 1,838 | — | — | $0 | 3 | 2019-12-06 |
| Carisma Therapeutics Inc. (EBIO) Delisted | Chief Financial Officer | 5,930 | — | — | -$9.0K | 9 | 2017-04-05 |
Recent Filings
12 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-12-06 | Adicet Bio, Inc. (TORC) Delisted | Grant (A) | +12,867 | $0 | EDGAR |
| 2019-02-28 | Adicet Bio, Inc. (TORC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-03-14 | Adicet Bio, Inc. (TORC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-04-05 | Carisma Therapeutics Inc. (EBIO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-02-16 | Carisma Therapeutics Inc. (EBIO) Delisted | Sell (S) | −1,399 | -$2.9K | EDGAR |
| 2016-09-22 | Carisma Therapeutics Inc. (EBIO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-08-17 | Carisma Therapeutics Inc. (EBIO) Delisted | Sell (S) | −1,170 | -$5.6K | EDGAR |
| 2016-07-12 | Carisma Therapeutics Inc. (EBIO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-06-17 | Carisma Therapeutics Inc. (EBIO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-02-29 | Carisma Therapeutics Inc. (EBIO) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.